Pharmaceutical

TYRA-200 by Tyra Biosciences for Bile Duct Cancer (Cholangiocarcinoma): Likelihood of Approval

TYRA-200 is under clinical development by Tyra Biosciences and currently in Phase I for Bile Duct Cancer (Cholangiocarcinoma).

Jun 20, 2024 - 04:00
TYRA-200 by Tyra Biosciences for Bile Duct Cancer (Cholangiocarcinoma): Likelihood of Approval
TYRA-200 is under clinical development by Tyra Biosciences and currently in Phase I for Bile Duct Cancer (Cholangiocarcinoma).
Read the original article

Tags:

Previous Article

SGNB-7H4V by Pfizer for Bile Duct Cancer (Cholangiocarcinoma): Likelihood of App...

Next Article

EHA 2024: Monoclonal antibodies continue to dominate multiple myeloma treatments

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Pharmalittle: Life sciences deals on track to hit lowest point since 2017; EU regulators order Illumina to divest Grail

STAT+: Pharmalittle: Life sciences deals on track to hi...

Oct 12, 2023

STAT+: Targeted drug greatly slows progression of a brain cancer

STAT+: Targeted drug greatly slows progression of a bra...

Jun 4, 2023

Soft, stretchable electronic skin could reconstruct the sense of touch

Soft, stretchable electronic skin could reconstruct the...

May 19, 2023